Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GSK names Witty CEO

GlaxoSmithKline (LSE:GSK; GSK) will promote Andrew Witty to CEO from president of

Read the full 123 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE